RCS - Nuformix PLC - NXP002 Update

NuformixAnnouncement

15/02/2023 07:16

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230215:nRSO8876Pa&default-theme=true

RNS Number : 8876P  Nuformix PLC  15 February 2023

REACH

 

15 February 2023

 

Nuformix plc

 

("Nuformix" or the "Company" or the "Group")

 

NXP002 Update

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, is pleased to
announce the following update regarding the Company's NXP002 programme, a
proprietary new form of tranilast, being developed as a novel inhaled
treatment for Idiopathic Pulmonary Fibrosis ("IPF").

 

As previously announced, the Company has initiated studies in 3D human IPF
lung tissue using a disease and species relevant model, and is working with
its partner, Fibrofind, focusing on NXP002 in combination with current
standards of care.  Suitable human disease tissue, which is highly limited in
supply, has now been acquired allowing the practical elements of the study to
commence, with results and further updates to be announced in due course.

 

NXP002 combinations have already shown promise in human diseased IPF tissue,
showing a pleasing synergistic efficacy effect with low doses of
standards-of-care, resulting in the Group filing a new combination patent
application in 2022.

 

Commenting, Dr Dan Gooding, Executive Director of Nuformix, said: "We've had
to wait a little longer than expected to acquire suitable tissue, but I'm
delighted that the main element of this key study, further evaluating NXP002
combination therapies is now underway and I look forward to sharing the
results when they are available."

 

 

Enquiries:

 

 Nuformix plc
 Dr Dan Gooding, Executive Director                Via IFC Advisory

 Stanford Capital Partners Limited
 Tom Price / Patrick Claridge (Corporate Finance)  +44 (0) 20 3650 3650
 John Howes (Corporate Broking)                    +44 (0) 20 3650 3652

 IFC Advisory Limited
 Tim Metcalfe                                      +44 (0) 20 3934 6630

 Zach Cohen                                        nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs
in fibrosis and oncology via drug repurposing. The Company aims to use its
expertise in discovering, developing and patenting novel drug forms, with
improved physical properties, to develop new products in new indications that
are, importantly, differentiated from the original (by way of dosage, delivery
route or presentation), thus creating new and attractive commercial
opportunities. Nuformix has a pipeline of preclinical assets with potential
for significant value and early licensing opportunities.

 

About Fibrosis

 

Fibrotic disease is typically associated with high patient mortality,
increasing prevalence and a lack of safe and effective treatments. Whilst
fibrosis treatments are in their infancy the emerging lung fibrosis market
demonstrates their blockbuster potential. Idiopathic Pulmonary Fibrosis is
classified as a rare disease and presents a global commercial market that is
forecast to grow to US$5bn by 2025. Sales of standard-of-care therapies OFEV
and Esbriet achieved US$2.58bn and US$1.04bn respectively in 2021.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRABZLFFXLLZBBK